Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia(R) for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a fully integrated biopharmaceutical company focused on bettering the lives of people impacted by kidney disease, today filed a complaint in federal district court...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P....

AKBA : 4.41 (+2.08%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced full enrollment of its global Phase 3 program evaluating the safety and efficacy of vadadustat for the treatment of anemia due to chronic kidney...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P....

AKBA : 4.41 (+2.08%)
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 4.41 (+2.08%)
Akebia Therapeutics: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $58.2 million in its second quarter.

AKBA : 4.41 (+2.08%)
Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today reported financial results...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics(R) Announces Settlement of Auryxia(R) Patent Litigation with Par Pharmaceutical

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion & BF Biotech, Inc., have entered into a Settlement and...

KERX : 3.36 (-2.04%)
AKBA : 4.41 (+2.08%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics to Report Second Quarter 2019 Financial Results

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease, today announced plans to release its...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics Announces Submission of Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that Mitsubishi Tanabe Pharma Corporation (MTPC), its development and commercialization collaboration partner in Japan for vadadustat, Akebia's...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners

Akebia Therapeutics, Inc. (Nasdaq: AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler,...

AKBA : 4.41 (+2.08%)
Akebia Therapeutics Announces Collaboration Partner's Positive Top-line Results of Phase 3 Clinical Study of Riona(R) (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line...

TRXPF : 25.8720 (+1.06%)
AKBA : 4.41 (+2.08%)
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board...

AKBA : 4.41 (+2.08%)
TRVN : 0.97 (+1.04%)
ACRS : 1.56 (+6.12%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14...

AKBA : 4.41 (+2.08%)
Akebia Therapeut Has Returned 29.2% Since SmarTrend Recommendation (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on April 4th, 2019 at $7.10. In approximately 2 months, Akebia Therapeut has returned 29.15% as of today's recent price of $5.03.

AKBA : 4.41 (+2.08%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced...

AKBA : 4.41 (+2.08%)
Downtrend Call Working As Akebia Therapeut Stock Falls 18.5% (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on April 4th, 2019 at $7.10. In approximately 1 month, Akebia Therapeut has returned 18.45% as of today's recent price of $5.79.

AKBA : 4.41 (+2.08%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.71 , AIZ +0.14 , SBAC -7.60 , SO +0.34 , WELL -0.64
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar